NO971342L - Pyrrolo£2,3-d|pyrimidiner og deres anvendelse - Google Patents

Pyrrolo£2,3-d|pyrimidiner og deres anvendelse

Info

Publication number: NO971342L
Authority: NO; Norway
Prior art keywords: compounds; alkyl; pct; trifluoromethyl; unsubstituted
Prior art date: 1994-09-29

Application number

NO971342A

Other languages

English (en)

Other versions

NO971342D0 (no

NO308108B1 (no

Inventor

Martin Missbach

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-29

Filing date

1997-03-21

Publication date

1997-03-21

1997-03-21 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1997-03-21 Publication of NO971342L publication Critical patent/NO971342L/no

1997-03-21 Publication of NO971342D0 publication Critical patent/NO971342D0/no

2000-07-24 Publication of NO308108B1 publication Critical patent/NO308108B1/no

Links

150000003230 pyrimidines Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
125000000217 alkyl group Chemical group 0.000 abstract 4
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Detergent Compositions (AREA)

NO971342A 1994-09-29 1997-03-21 Pyrrolo[2,3-d]pyrimidiner og deres anvendelse for fremstilling av et medikament NO308108B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH295394		1994-09-29
PCT/EP1995/003536 WO1996010028A1 (en)	1994-09-29	1995-09-08	PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE

Publications (3)

Publication Number	Publication Date
NO971342L true NO971342L (no)	1997-03-21
NO971342D0 NO971342D0 (no)	1997-03-21
NO308108B1 NO308108B1 (no)	2000-07-24

Family

ID=4245363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO971342A NO308108B1 (no)	1994-09-29	1997-03-21	Pyrrolo[2,3-d]pyrimidiner og deres anvendelse for fremstilling av et medikament

Country Status (20)

Country	Link
US (1)	US5869485A (no)
EP (1)	EP0783505B1 (no)
JP (1)	JP4145955B2 (no)
KR (1)	KR970706288A (no)
CN (1)	CN1046731C (no)
AT (1)	ATE199553T1 (no)
AU (1)	AU694801B2 (no)
BR (1)	BR9509048A (no)
CA (1)	CA2200210A1 (no)
DE (1)	DE69520282T2 (no)
DK (1)	DK0783505T3 (no)
ES (1)	ES2157344T3 (no)
FI (1)	FI112867B (no)
GR (1)	GR3035996T3 (no)
HU (1)	HU222181B1 (no)
MX (1)	MX9702307A (no)
NO (1)	NO308108B1 (no)
NZ (1)	NZ293249A (no)
PT (1)	PT783505E (no)
WO (1)	WO1996010028A1 (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
EP0836605B1 (en) *	1995-07-06	2002-02-06	Novartis AG	Pyrrolopyrimidines and processes for the preparation thereof
AU3176297A (en) *	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
JP4056589B2 (ja) *	1996-07-19	2008-03-05	武田薬品工業株式会社	複素環化合物、その製造法および用途
CA2260999C (en) *	1996-07-19	2006-07-11	Takeda Chemical Industries, Ltd.	Heterocyclic compounds, their production and use in tyrosine kinase inhibition
AU720429B2 (en)	1996-08-23	2000-06-01	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
ES2239779T3 (es)	1996-10-02	2005-10-01	Novartis Ag	Derivados de pirimidina y procedimientos para la preparacion de los mismos.
GB9704948D0 (en)	1997-03-11	1997-04-30	Knoll Ag	Therapeutic agents
TR199902301T2 (xx) *	1997-03-19	1999-12-21	Basf Aktiengesellschaft	Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
IL133430A0 (en) *	1997-08-05	2001-04-30	Pfizer Prod Inc	4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
IL139787A0 (en) *	1998-06-02	2002-02-10	Osi Pharm Inc	PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
HK1039326A1 (zh) *	1998-09-18	2002-04-19	Abbott Gmbh & Co. Kg	4氨基吡咯并嘧啶作为激酶抑制剂
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
US7125875B2 (en)	1999-04-15	2006-10-24	Bristol-Myers Squibb Company	Cyclic protein tyrosine kinase inhibitors
KR20020088406A (ko)	1999-09-17	2002-11-27	애보트 게엠베하 운트 콤파니 카게	치료제로서의 피라졸로피리미딘
US7071199B1 (en)	1999-09-17	2006-07-04	Abbott Gmbh & Cco. Kg	Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
CN1523991A (zh)	2001-08-10	2004-08-25	��˹��ŵ��	单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
US6770652B2 (en) *	2001-10-18	2004-08-03	Duquesne University Of The Holy Ghost	Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) *	2001-12-24	2003-07-03	Merck Patent Gmbh	Pyrrolo-pyrimidine
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
GB0226370D0 (en) *	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
US7157460B2 (en) *	2003-02-20	2007-01-02	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CA2553724A1 (en) *	2004-02-03	2005-08-18	Abbott Laboratories	Aminobenzoxazoles as therapeutic agents
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
ES2436877T3 (es) *	2005-11-17	2014-01-07	OSI Pharmaceuticals, LLC	Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
TW200801008A (en) *	2005-12-29	2008-01-01	Abbott Lab	Protein kinase inhibitors
US7659274B2 (en) *	2006-01-25	2010-02-09	Osi Pharmaceuticals, Inc.	Unsaturated mTOR inhibitors
JP2011515410A (ja) *	2008-03-19	2011-05-19	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	塩の形のｍＴＯＲ阻害剤
CA2740885C (en) *	2008-10-16	2018-04-03	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
WO2010066629A2 (en) *	2008-12-09	2010-06-17	F. Hoffmann-La Roche Ag	Novel azaindoles
AU2010294209A1 (en)	2009-09-10	2012-03-29	Irm Llc	Ether derivatives of bicyclic heteroaryls
WO2011064211A1 (en)	2009-11-25	2011-06-03	Novartis Ag	Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CN102947274A (zh)	2010-06-17	2013-02-27	诺瓦提斯公司	联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
EP2582681A1 (en)	2010-06-17	2013-04-24	Novartis AG	Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN103492390A (zh)	2011-03-08	2014-01-01	诺瓦提斯公司	氟苯基双环杂芳基化合物
AU2012225232B2 (en)	2011-03-09	2016-05-12	Richard G. Pestell	Prostate cancer cell lines, gene signatures and uses thereof
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EP2861302A4 (en)	2012-05-14	2016-08-24	Prostagene Llc	USE OF CCR5 MODULATORS FOR THE TREATMENT OF CANCER
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN108064274A (zh)	2014-07-30	2018-05-22	耶达研究及发展有限公司	用于培养多能干细胞的培养基
US10550124B2 (en) *	2015-08-13	2020-02-04	San Diego State University Foundation	Atropisomerism for increased kinase inhibitor selectivity
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
MX2021012639A (es)	2016-11-18	2022-10-03	Cystic Fibrosis Found	Pirrolopirimidinas como potenciadores de cftr.
AU2017444054B2 (en)	2017-12-21	2021-10-07	Hefei Institutes Of Physical Science, Chinese Academy Of Sciences	Class of pyrimidine derivative kinase inhibitors
EP3886854A4 (en)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
EP3914698B1 (en)	2019-01-23	2024-12-11	Yeda Research and Development Co. Ltd	Culture media for pluripotent stem cells
JP2022553376A (ja) *	2019-10-25	2022-12-22	アクセント・セラピューティクス・インコーポレイテッド	Ｍｅｔｔｌ３モジュレーター
US20220395553A1 (en)	2019-11-14	2022-12-15	Cohbar, Inc.	Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung

1995
- 1995-09-08 JP JP51131296A patent/JP4145955B2/ja not_active Expired - Fee Related
- 1995-09-08 CA CA002200210A patent/CA2200210A1/en not_active Abandoned
- 1995-09-08 CN CN95196308A patent/CN1046731C/zh not_active Expired - Fee Related
- 1995-09-08 HU HU9701333A patent/HU222181B1/hu not_active IP Right Cessation
- 1995-09-08 AT AT95932693T patent/ATE199553T1/de not_active IP Right Cessation
- 1995-09-08 ES ES95932693T patent/ES2157344T3/es not_active Expired - Lifetime
- 1995-09-08 NZ NZ293249A patent/NZ293249A/en active IP Right Revival
- 1995-09-08 MX MX9702307A patent/MX9702307A/es not_active IP Right Cessation
- 1995-09-08 DK DK95932693T patent/DK0783505T3/da active
- 1995-09-08 AU AU35643/95A patent/AU694801B2/en not_active Ceased
- 1995-09-08 DE DE69520282T patent/DE69520282T2/de not_active Expired - Lifetime
- 1995-09-08 EP EP95932693A patent/EP0783505B1/en not_active Expired - Lifetime
- 1995-09-08 US US08/793,313 patent/US5869485A/en not_active Expired - Lifetime
- 1995-09-08 WO PCT/EP1995/003536 patent/WO1996010028A1/en not_active Ceased
- 1995-09-08 PT PT95932693T patent/PT783505E/pt unknown
- 1995-09-08 KR KR1019970702044A patent/KR970706288A/ko not_active Abandoned
- 1995-09-08 BR BR9509048A patent/BR9509048A/pt not_active IP Right Cessation
1997
- 1997-03-21 NO NO971342A patent/NO308108B1/no not_active IP Right Cessation
- 1997-03-24 FI FI971225A patent/FI112867B/fi active
2001
- 2001-06-06 GR GR20010400849T patent/GR3035996T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ293249A (en)	1999-04-29
BR9509048A (pt)	1998-01-06
CN1164234A (zh)	1997-11-05
HU222181B1 (hu)	2003-04-28
DE69520282T2 (de)	2001-08-09
DE69520282D1 (de)	2001-04-12
CA2200210A1 (en)	1996-04-04
ES2157344T3 (es)	2001-08-16
FI971225L (fi)	1997-05-14
JP4145955B2 (ja)	2008-09-03
DK0783505T3 (da)	2001-07-02
JPH10506624A (ja)	1998-06-30
PT783505E (pt)	2001-08-30
HUT76785A (en)	1997-11-28
FI112867B (fi)	2004-01-30
GR3035996T3 (en)	2001-09-28
ATE199553T1 (de)	2001-03-15
KR970706288A (ko)	1997-11-03
AU3564395A (en)	1996-04-19
FI971225A0 (fi)	1997-03-24
CN1046731C (zh)	1999-11-24
WO1996010028A1 (en)	1996-04-04
AU694801B2 (en)	1998-07-30
EP0783505A1 (en)	1997-07-16
MX9702307A (es)	1998-04-30
US5869485A (en)	1999-02-09
EP0783505B1 (en)	2001-03-07
NO971342D0 (no)	1997-03-21
NO308108B1 (no)	2000-07-24

Legal Events

Date	Code	Title	Description
2011-05-09	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO971342D0 (no)	1997-03-21	Pyrrolo£2,3-d\|pyrimidiner og deres anvendelse
NO951684L (no)	1995-11-06	Pyrrolopyrimidinderivater med farmakologisk aktivitet
MD1616G2 (ro)	2001-11-30	Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor
EA200200473A1 (ru)	2002-10-31	Ингибиторы тирозинкиназы
ATE316088T1 (de)	2006-02-15	Tyrosin-kinase inhibitoren
CY1105618T1 (el)	2010-12-22	Δικυκλικες ετεροαρωματικες ενωσεις ως αναστολεις της κινασης τυροσινης πρωτεϊνης
AP2002002643A0 (en)	2002-12-31	5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
ES2193362T3 (es)	2003-11-01	Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos.
NO975956D0 (no)	1997-12-18	Pyrrolopyrimidiner og fremgangsmåter for deres fremstilling
DK0938486T3 (da)	2008-07-07	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
MY134848A (en)	2007-12-31	Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
NZ333706A (en)	2000-08-25	Benzenesulfone derivatives and medicaments
EA200400006A1 (ru)	2004-06-24	Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
ATE309241T1 (de)	2005-11-15	Tyrosin kinase inhibitoren
ATE290865T1 (de)	2005-04-15	Tyrosin kinase inhibitoren
BR9709443B1 (pt)	2009-05-05	n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
ATE146781T1 (de)	1997-01-15	Chinazolinderivate enthaltende therapeutische zusammensetzungen
DE69833797D1 (de)	2006-05-04	Substituierte 2-benzylamino-2-phenyl-acetamidverbindungen
MXPA05010975A (es)	2005-11-28	Derivados de (6-(fenoxi)-pirido[3,4-d]pirimidin-2-il)-amina como inhibidores de p38 cinasa para el tratamiento de condiciones inflamatorias como artritis reumatoide.
DK0526588T3 (da)	1994-08-22	Heterocykliske forbindelser, deres fremstilling og anvendelse
UA41281C2 (uk)	2001-09-17	Тіоксантенонові сполуки, фармацевтична композиція на їх основі з протипухлинною активністю
ES503093A0 (es)	1982-04-01	Procedimiento para preparar difenilbutil-1-acilpiperazinas
UY26866A1 (es)	2001-09-28	Proceso para preparar 2-(4-piridil) amino-6-dialquiloxifenilpirido (2,3-d) pirimidin-7-onas
UA87895C2 (en)	2009-08-25	Substituted 5-phenyl pyrimidines i in therapy
ES2193047T3 (es)	2003-11-01	(3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.